Silvan Tuerkcan
Stock Analyst at Citizens Capital Markets
(2.00)
# 2,792
Out of 4,760 analysts
151
Total ratings
35.37%
Success rate
-9.12%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Reiterates: Market Outperform | $7 | $0.51 | +1,270.13% | 6 | Mar 10, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $5.69 | +163.48% | 2 | Mar 7, 2025 | |
| PRME Prime Medicine | Reiterates: Market Outperform | $10 | $1.90 | +426.32% | 2 | Mar 4, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $43.42 | +98.07% | 14 | Feb 13, 2025 | |
| EXEL Exelixis | Maintains: Market Outperform | $41 | $37.00 | +10.81% | 20 | Jan 27, 2025 | |
| JSPR Jasper Therapeutics | Reiterates: Market Outperform | $70 | $5.47 | +1,179.71% | 5 | Jan 10, 2025 | |
| CNTX Context Therapeutics | Initiates: Market Outperform | $4 | $0.71 | +463.38% | 1 | Jan 8, 2025 | |
| ENGN enGene Holdings | Reiterates: Market Outperform | $18 | $5.15 | +249.51% | 3 | Dec 23, 2024 | |
| RLAY Relay Therapeutics | Reiterates: Market Outperform | $21 | $3.51 | +498.29% | 10 | Dec 12, 2024 | |
| VOR Vor Biopharma | Reiterates: Market Outperform | $12 | $0.86 | +1,292.27% | 11 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $3.57 | +460.87% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $1.72 | +190.28% | 11 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.45 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $16 → $18 | $13.78 | +30.62% | 9 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $5.35 | +217.76% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.27 | +372.44% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $248.38 | +12.73% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.53 | - | 7 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $13.40 | +34.33% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.48 | - | 10 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $2 → $3 | $7.18 | -58.22% | 3 | May 10, 2022 |
Elevation Oncology
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $7
Current: $0.51
Upside: +1,270.13%
Solid Biosciences
Mar 7, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.69
Upside: +163.48%
Prime Medicine
Mar 4, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $1.90
Upside: +426.32%
CRISPR Therapeutics AG
Feb 13, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $43.42
Upside: +98.07%
Exelixis
Jan 27, 2025
Maintains: Market Outperform
Price Target: $41
Current: $37.00
Upside: +10.81%
Jasper Therapeutics
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $70
Current: $5.47
Upside: +1,179.71%
Context Therapeutics
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.71
Upside: +463.38%
enGene Holdings
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $18
Current: $5.15
Upside: +249.51%
Relay Therapeutics
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.51
Upside: +498.29%
Vor Biopharma
Dec 10, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $0.86
Upside: +1,292.27%
Dec 4, 2024
Reiterates: Market Outperform
Price Target: $20
Current: $3.57
Upside: +460.87%
Nov 12, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.72
Upside: +190.28%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.45
Upside: -
Oct 14, 2024
Maintains: Market Outperform
Price Target: $16 → $18
Current: $13.78
Upside: +30.62%
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $5.35
Upside: +217.76%
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.27
Upside: +372.44%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $248.38
Upside: +12.73%
Oct 23, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.53
Upside: -
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $13.40
Upside: +34.33%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.48
Upside: -
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $7.18
Upside: -58.22%